Following the patent expiry of Novo Nordisk’s semaglutide on March 20, 2026, Indian drugmakers including Natco, Dr. Reddy’s, and Eris are launching generic versions at 70-90% discounts.

Eli Lilly (LLY 0.11%) and Vertex Pharmaceuticals (VRTX +0.45%) have several things in common. Both are among the more prominent drugmakers in the world, and both have delivered ma ...

Amgen stock holds above key SMAs as strong drug sales, biosimilars, and MariTide pipeline momentum offset looming patent losses and pricing headwinds.

Trading in Eli Lilly and Company LLYis quiet on Wednesday. This follows yesterday's drop of almost 6%. The move was driven by a downgrade. But the selloff may be over. A reversal could even occur. The ...

Eli Lilly LLY remains a dominant player in the global obesity market, with much of its recent growth driven by itsblockbuster ...

HSBC analysts just slashed their recommendation on the world's most valuable pharmaceutical company, Eli Lilly, signaling a potential cooling period for the red-hot obesity drug trade that has come to ...

Eli Lilly shares are down 6% Tuesday and on pace for their worst day since February after an HSBC downgrade. The crux of HSBC ...

Eli Lilly (NYSE:LLY) stock is down 5% in Tuesday afternoon trading, with shares falling to $937 from a prior close of $989.12. The move adds to a rough stretch for the stock, which is now down 13% ...

Eli Lilly (NYSE:LLY) shares have pulled back sharply, falling  9% over the past month, and 13% year-to-date. Most Wall Street analysts remain constructive, with a consensus price target of $1,216.93 ...

Eli Lilly (LLY) stock declined after HSBC downgrade to Reduce with $850 price target, citing obesity drug market risks and ...

Eli Lilly (LLY) stock is lower today, after HSBC downgraded it to "reduce" from "hold," citing an inflated obesity drug market ...

Eli Lilly's growth rate has accelerated significantly in recent years due to its GLP-1 drugs. The stock, however, trades at ...